Stable pharmaceutical composition useful for treating gastrointestinal disorders
View Patent ↗The present invention provides a pharmaceutical composition comprising at least one pharmaceutically acceptable bismuth-containing compound, at least one pharmaceutically acceptable non-clay-derived suspending agent, and water. The suspension exhibits reduced upward pH drift by comparison with an otherwise similar suspension which comprises a clay-derived suspending agent. Such compositions are useful in the prevention and treatment of gastrointestinal diseases and/or disorders.
1. An orally deliverable liquid pharmaceutical suspension comprising:
(a) at least one pharmaceutically acceptable bismuth-containing compound present in a total amount of about 0.1 % to about 10%, by weight;
(b) an effective suspending amount of at least one pharmaceutically acceptable non-clay-derived suspending agent selected from the group consisting of cellulosic suspending agents, polymeric suspending agents, xanthan gum, silicon dioxide, and mixtures thereof;
(c) at least one pharmaceutically acceptable anti-microbial preservative, wherein the preservative does not contain benzoic acid or salts thereof; and
(d) water;
wherein during storage in a closed container maintained under ambient conditions for a period of at least about 5 months, the suspension exhibits reduced upward pH drift by comparison with an otherwise similar comparative suspension that contains at least 0.1%, by weight, of magnesium aluminum silicate.
2. The suspension of claim 1 comprising substantially no amount of a clay-derived suspending agent.
3. The suspension of claim 1 wherein the at least one pharmaceutically acceptable bismuth-containing compound is selected from the group consisting of bismuth aluminate, bismuth subcarbonate, bismuth subcitrate, bismuth nitrate, bismuth citrate, tripotassium dicitrato bismuthate, bismuth subgallate, bismuth subnitrate, bismuth tartrate, bismuth subsalicylate, and mixtures thereof.
4. The suspension of claim 1 wherein the at least one pharmaceutically acceptable bismuth-containing compound is bismuth subsalicylate.
5. The suspension of claim 1 wherein the at least one pharmaceutically acceptable bismuth-containing compound is present in a total amount of about 0.5% to about 5%, by weight.
6. The suspension of claim 1 wherein the at least one pharmaceutically acceptable non-clay-derived suspending agent is a polymer.
7. The suspension of claim 1 wherein the at least one pharmaceutically acceptable non-clay-derived suspending agent is selected from the group consisting of methylcellulose, hydroxypropylmethylcellulose, hydroxybutylmethylcellulose, hydroxyethylmethylcellulose, ethylhydroxyethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose sodium, microcrystalline cellulose, xanthan gum, silicon dioxide, and mixtures thereof.
8. The suspension of claim 1 wherein the non-clay-derived suspending agent is a mixture of two or more of microcrystalline cellulose, carboxymethylcellulose sodium and xanthan gum.
9. The suspension of claim 1 wherein the at least one pharmaceutically acceptable non-clay-derived suspending agent is present in a total amount of about 0.0 1% to about 15%, by weight.
10. The suspension of claim 1 wherein the at least one pharmaceutically acceptable non-clay-derived suspending agent is present in a total amount of about 0.1% to about 5%, by weight.
11. The suspension of claim 1 wherein the at least one pharmaceutically acceptable anti-microbial preservative is selected from the group consisting of butylparaben, editic acid, ethylparaben, glycerol, methylparaben, potassium sorbate, propionic acid, propylene glycol, propylparaben, salicylic acid, sorbic acid, sodium propionate, sodium salicylate, and mixtures thereof.
12. The suspension of claim 1 wherein the at least one pharmaceutically acceptable anti-microbial preservative is selected from the group consisting of sorbic acid, methylparaben, sodium salicylate, salicylic acid, and mixtures thereof.
13. The suspension of claim 1 wherein the at least one pharmaceutically acceptable anti-microbial preservative is present in a total amount of about 0.01% to about 10%, by weight.
14. The suspension of claim 1 wherein the at least one pharmaceutically acceptable anti-microbial preservative is present in a total amount of about 0.01 % to about 2.5%, by weight.
15. The suspension of claim 1 having a pH, measured immediately after preparation, of about 2 to about 8.
16. The suspension of claim 1 having a pH, measured immediately after preparation, of about 3 to about 7.
17. The suspension of claim 1 wherein, during storage in a closed container maintained under ambient conditions for a period of at least about 5 months, the suspension exhibits an upward pH drift of not more than about 0.6.
18. The suspension of claim 1 wherein, during storage in a closed container maintained under ambient conditions for a period of at least about 5 months, the suspension exhibits an upward pH drift of not more than about 0.1.
19. The suspension of claim 1 wherein, during storage in a closed container maintained under ambient conditions for a period of at least about 5 months, the suspension exhibits substantially no upward pH drift.
20. The suspension of claim 1 wherein, during storage in a closed container maintained under ambient conditions for a period of at least about 12 months, the suspension exhibits substantially no upward pH drift.
21. The suspension of claim 1 wherein the water is present in a total amount of about 50% to about 99%, by weight.
22. The suspension of claim 1 wherein the water is present in a total amount of about 65% to about 92.5%, by weight.
23. An orally deliverable liquid pharmaceutical suspension comprising:
(a) at least one pharmaceutically acceptable bismuth-containing compound;
(b) an effective suspending amount of at least one pharmaceutically acceptable non-clay-derived suspending agent selected from the group consisting of cellulosic suspending agents, polymeric suspending agents, xanthan gum, silicon dioxide, and mixtures thereof;
(c) at least one pharmaceutically acceptable anti-microbial preservative, wherein the preservative does not contain benzoic acid or salts thereof; and
(d) water;
wherein the suspension comprises zero to not more than 0.08%, by weight, of a clay-derived suspending agent and wherein the suspension has a pH, measured immediately after preparation, of about 2 to about 8.
24. The suspension of claim 23 comprising substantially no amount of a clay-derived suspending agent.
25. The suspension of claim 23 wherein the at least one pharmaceutically acceptable bismuth-containing compound is selected from the group consisting of bismuth aluminate, bismuth subcarbonate, bismuth subcitrate, bismuth nitrate, bismuth citrate, tripotassium dicitrato bismuthate, bismuth subgallate, bismuth subnitrate, bismuth tartrate, bismuth subsalicylate and mixtures thereof.
26. The suspension of claim 23 wherein the at least one pharmaceutically acceptable bismuth-containing compound is bismuth subsalicylate.
27. The suspension of claim 23 wherein the at least one pharmaceutically acceptable bismuth-containing compound is present in a total amount of about 0.01% to about 50%, by weight.
28. The suspension of claim 23 wherein the at least one pharmaceutically acceptable bismuth-containing compound is present in a total amount of about 0.5% to about 5%, by weight.
29. The suspension of claim 23 wherein the at least one pharmaceutically acceptable non-clay-derived suspending agent is a polymer.
30. The suspension of claim 23 wherein the at least one pharmaceutically acceptable non-clay-derived suspending agent is selected from the group consisting of methylcellulose, hydroxypropylmethylcellulose, hydroxybutylmethylcellulose, hydroxyethylmethylcellulose, ethylhydroxyethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose sodium, microcrystalline cellulose, xanthan gum, silicon dioxide, and mixtures thereof.
31. The suspension of claim 23 wherein the non-clay-derived suspending agent is a mixture of two or more of microcrystalline cellulose, carboxymethylcellulose sodium and xanthan gum.
32. The suspension of claim 23 wherein the at least one pharmaceutically acceptable non-clay-derived suspending agent is present in a total amount of about 0.01% to about 15%, by weight.
33. The suspension of claim 23 wherein the at least one pharmaceutically acceptable non-clay-derived suspending agent is present in a total amount of about 0.1% to about 5%, by weight.
34. The suspension of claim 23 wherein the at least one pharmaceutically acceptable anti-microbial preservative is selected from the group consisting of butylparaben, editic acid, ethylparaben, glycerol, methylparaben, potassium sorbate, propionic acid, propylene glycol, propylparaben, salicylic acid, sorbic acid, sodium propionate, sodium salicylate, and mixtures thereof.
35. The suspension of claim 23 wherein the at least one pharmaceutically acceptable anti-microbial preservative is selected from the group consisting of sorbic acid, methylparaben, sodium salicylate, salicylic acid, and mixtures thereof.
36. The suspension of claim 23 wherein the at least one pharmaceutically acceptable anti-microbial preservative is present in a total amount of about 0.01% to about 10%, by weight.
37. The suspension of claim 23 wherein the at least one pharmaceutically acceptable anti-microbial preservative is present in a total amount of about 0.01% to about 2.5%, by weight.
38. The suspension of claim 23 having a pH, measured immediately after preparation, of about 3 to about 7.
39. The suspension of claim 23 having a pH, measured immediately after preparation, of about 3.5 to about 6.
40. The suspension of claim 23 wherein, during storage in a closed container maintained under ambient conditions for a period of at least about 5 months, the suspension exhibits an upward pH drift of not more than about 0.6.
41. The suspension of claim 23 wherein, during storage in a closed container maintained under ambient conditions for a period of at least about 5 months, the suspension exhibits an upward pH drift of not more than about 0.1.
42. The suspension of claim 23 wherein, during storage in a closed container maintained under ambient conditions for a period of at least about 5 months, the suspension exhibits substantially no upward pH drift.
43. The suspension of claim 23 wherein, during storage in a closed container maintained under ambient conditions for a period of at least about 12 months, the suspension exhibits substantially no upward pH.
44. The suspension of claim 23 wherein the water is present in a total amount of about 50% to about 99%, by weight.
45. The suspension of claim 23 wherein the water is present in a total amount of about 65% to about 92.5%, by weight.
46. An orally deliverable liquid pharmaceutical suspension comprising:
(a) at least one pharmaceutically acceptable bismuth-containing compound present in a total amount of about 0.5% to about 5%, by weight;
(b) at least one pharmaceutically acceptable non-clay-derived suspending agent selected from the group consisting of cellulosic suspending agents, polymeric suspending agents, xanthan gum, silicon dioxide, and mixtures thereof, wherein the at least one pharmaceutically acceptable non-clay-derived suspending agent is present in a total amount of about 0.1 % to about 5%, by weight;
(c) at least one pharmaceutically acceptable anti-microbial preservative present in a total amount of about 0.01% to about 5%, by weight, wherein the preservative does not contain benzoic acid or salts thereof; and
(d) water;
wherein the suspension comprises not more than 0.08%, by weight, of a clay-derived suspending agent and wherein the suspension has a pH, measured immediately after preparation, of about 2 to about 8.
47. The suspension of claim 46 comprising substantially no amount of a clay-derived suspending agent.
48. The suspension of claim 46 wherein the at least one pharmaceutically acceptable bismuth-containing compound is selected from the group consisting of bismuth aluminate, bismuth subcarbonate, bismuth subcitrate, bismuth nitrate, bismuth citrate, tripotassium dicitrato bismuthate, bismuth subgallate, bismuth subnitrate, bismuth tartrate, bismuth subsalicylate and mixtures thereof.
49. The suspension of claim 46 wherein the at least one pharmaceutically acceptable bismuth-containing compound is bismuth subsalicylate.
50. The suspension of claim 46 wherein the at least one pharmaceutically acceptable non-clay-derived suspending agent is a polymer.
51. The suspension of claim 46 wherein the at least one pharmaceutically acceptable non-clay-derived suspending agent is selected from the group consisting of methylcellulose, hydroxypropylmethylcellulose, hydroxybutylmethylcellulose, hydroxyethylmethylcellulose, ethylhydroxyethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose sodium, microcrystalline cellulose, xanthan gum, silicon dioxide, and mixtures thereof.
52. The suspension of claim 46 wherein the non-clay-derived suspending agent is a mixture of two or more of microcrystalline cellulose, carboxymethylcellulose sodium and xanthan gum.
53. The suspension of claim 46 wherein the at least one pharmaceutically acceptable anti-microbial preservative is selected from the group consisting of butylparaben, editic acid, ethylparaben, glycerol, methylparaben, potassium sorbate, propionic acid, propylene glycol, propylparaben, salicylic acid, sorbic acid, sodium propionate, sodium salicylate, and mixtures thereof.
54. The suspension of claim 46 wherein the at least one pharmaceutically acceptable anti-microbial preservative is selected from the group consisting of sorbic acid, methylparaben, sodium salicylate, salicylic acid, and mixtures thereof.
55. The suspension of claim 46 having a pH, measured immediately after preparation, of about 3 to about 7.
56. The suspension of claim 46 having a pH, measured immediately after preparation, of about 3.5 to about 6.
57. The suspension of claim 47 wherein, during storage in a closed container maintained under ambient conditions for a period of at least about 5 months, the suspension exhibits upward pH drift of not more than about 0.6.
58. The suspension of claim 47 wherein, during storage in a closed container maintained under ambient conditions for a period of at least about 5 months, the suspension exhibits upward pH drift of not more than about 0.1.
59. The suspension of claim 46 wherein, during storage in a closed container maintained under ambient conditions for a period of at least about 5 months, the suspension exhibits substantially no upward pH drift.
60. The suspension of claim 46 wherein, during storage in a closed container maintained under ambient conditions for a period of at least about 12 months, the suspension exhibits substantially no upward pH drift.
61. An orally deliverable liquid pharmaceutical suspension comprising:
(a) at least one pharmaceutically acceptable bismuth-containing compound present in a total amount of about 0.1% to about 10%, by weight;
(b) an effective suspending amount of at least one pharmaceutically acceptable non-clay-derived suspending agent selected from the group consisting of cellulosic suspending agents, polymeric suspending agents, xanthan gum, silicon dioxide, and mixtures thereof;
(c) at least one pharmaceutically acceptable anti-microbial preservative, wherein the preservative does not contain benzoic acid or salts thereof; and
(d) water;
wherein during storage in a closed container maintained under ambient conditions for a period of at least about 5 months, the suspension exhibits an average increase in pH of zero to not more than 0.06/month.
62. The suspension of claim 61 wherein during storage in a closed container maintained under ambient conditions for a period of at least about 24 months, the suspension exhibits an average increase in pH of zero to not more than 0.06/month.
63. The suspension of claim 61 wherein during storage in a closed container maintained under ambient conditions for a period of at least about 5 months, the suspension exhibits an average increase in pH of zero to not more than 0.004/month.
64. The suspension of claim 61 wherein during storage in a closed container maintained under ambient conditions for a period of at least about 24 months, the suspension exhibits an average increase in pH of zero to not more than 0.004/month.
65. A method of treating a gastrointestinal disease and/or disorder in a subject in need of such treatment, comprising oral administration to the subject of a therapeutically effective amount of a suspension of claim 1 , claim 23 , claim 46 or claim 61 .